Chiral amino acid detection kit and application thereof in bladder cancer diagnosis and recurrence monitoring

By using stable isotope-labeled chiral derivatization reagents, the difficulties of chiral amino acid isolation and quantitative detection in bladder cancer diagnosis are solved, and high sensitivity and specific bladder cancer detection is achieved, suitable for the diagnosis and recurrence monitoring of bladder cancer.

CN118914569APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411129901.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has difficulties in the isolation and quantitative detection of chiral amino acids in the diagnosis of bladder cancer, especially the isolation of D- and L-amino acids is relatively challenging, resulting in low sensitivity and poor specificity to low-grade tumors.

Method used

Chiral derivatization reagents based on stable isotope labeling, including d0-N,N-dimethylphenylalanine succinimide and d4-N,N-dimethylphenylalanine succinimide , through HPLC-MS/MS detection, the separation and quantitative detection of multiple pairs of D/L-amino acids are achieved, and the sensitivity, accuracy and precision of the detection are improved.

Benefits of technology

High sensitivity, specificity and accuracy detection for bladder cancer has been achieved, the detection difficulties of the prior art have been overcome, and an effective chiral amino acid kit is provided for the diagnosis and recurrence monitoring of bladder cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914569A_ABST
    Figure CN118914569A_ABST
Patent Text Reader

Abstract

The invention discloses a chiral amino acid detection kit and application thereof in bladder cancer diagnosis and recurrence monitoring, the chiral amino acid detection kit comprises an amino acid standard substance and a derivatization reagent for derivatizing the amino acid standard substance and a sample containing amino acid, the derivatization reagent is a chiral derivatization reagent based on stable isotope labeling, and comprises d0-N, N-dimethyl phenylalanine succinimide ester and d4-N, N-dimethyl phenylalanine succinimide ester. The chiral derivatization reagent based on stable isotope labeling is adopted, resolution and quantitative detection of more than 20 pairs of D / L-amino acids can be achieved through the chiral derivatization reagent, and high sensitivity, accuracy, precision and stability are achieved; the technical problem that an existing chiral amino acid detection technology can only be used for splitting and quantifying a small amount of chiral amino acid is solved, and the method can be used for bladder cancer diagnosis and recurrence monitoring and has important clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of kits, and in particular to a chiral amino acid detection kit and application thereof in bladder cancer diagnosis and recurrence monitoring. Background Art

[0002] Bladder cancer (BCa) is a common malignant tumor of the male urinary system and one of the top ten most common cancers in the world. Currently, cystoscopy and histological pathological evaluation are still the gold standard for diagnosing bladder cancer, but this method has low sensitivity for small papillary tumors (Ta, T1 stage) and Tis stage tumors. If the diagnosis is not timely, about half of the untreated patients will develop into muscle-invasive tumors. In addition, the invasiveness and high price of the test cause certain physical damage and economic burden to patients.

[0003] Non-invasive urine cytology has been developed clinically. For example, urine cytology has a high diagnostic accuracy for high-grade lesions and Tis stage tumors, with a sensitivity of 80-90% and a specificity of 98-100%, but its sensitivity for low-grade tumors is lower, ranging between 4% and 31%, and the false positive rate is high. In addition, the US Food and Drug Administration (FDA) has approved some non-invasive urine tests for bladder cancer diagnosis, such as bladder tumor-associated antigen (BTA TRAK®, BTA stat®), nuclear matrix protein (NMP22), cell-based immunofluorescence detection (ImmunoCyt / uCyt), and fluorescence in situ hybridization (FISH)-based detection (UroVysion®). The overall performance of these reagents is encouraging, but when evaluating the results in an independent patient population, this performance is not very good and the specificity is poor.

[0004] The bladder mainly stores and excretes urine produced by the kidneys, and urine may come into direct contact with bladder cancer. The collected urine may contain molecules (proteins, metabolic small molecules) secreted or shed from tumor tissues. These molecules (especially chiral amino acids) may be related to the occurrence or development of tumors, so specific disease markers may exist in urine samples. In addition, compared with serum or plasma, urine sampling is simple, low-cost, uncomplicated and non-invasive. More importantly, urine can reflect changes in the body due to disease earlier and more sensitively.

[0005] Chiral amino acids are commonly found in urine, and changes in the levels of chiral amino acids in urine are often associated with physical diseases. However, the structures of D / L-amino acids are highly similar, and the content of D-amino acids in biological samples is relatively low. They are easily interfered by proteins, L-amino acids, and nucleotides, which poses a challenge to the separation of D- and L-amino acids in chromatography. Therefore, how to overcome the difficulty of separating D- and L-amino acids is crucial to the development of a new chiral amino acid kit for the diagnosis of primary and recurrent bladder cancer. Summary of the invention

[0006] In view of this, the present invention provides a chiral amino acid detection kit and also provides the use of the chiral amino acid detection kit in bladder cancer diagnosis and recurrence monitoring.

[0007] To achieve the above object, the present invention adopts the following technical solutions: The chiral amino acid detection kit of the present invention comprises an amino acid standard and a derivatization reagent for derivatizing the amino acid standard and a sample containing amino acids; wherein: The amino acid standard comprises any one or a combination of two or more of D / L-Ala, D / L-Val, Leu, D / L-Ile, D / L-Met, D / L-Pro, D / L-Trp, D / L-Ser, D / L-Tyr, D / L-Phe, D / L-Asn, D / L-Gln, D / L-Thr, D / L-Asp, D / L-Glu, D / L-Lys, D / L-Arg, D / L-His, D / L-Homoser, D / L-Orn, D / L-Cit, D / L-Kynu, D / L-Abu and Gly; The derivatization reagent is a chiral derivatization reagent based on stable isotope labeling, including d 0 -N,N-dimethylphenylalanine succinimidyl ester and d 4 -N,N-dimethylphenylalanine succinimide ester, the general structural formula is: ; Among them, when R1 is CH3 and R2 is CH3, d 0 -N,N-dimethylphenylalanine succinimide ester, when R1 is CHD2 and R2 is CHD2 d 4 -N,N-Dimethylphenylalanine succinimidyl ester.

[0008] The beneficial effect is that the present invention adopts a chiral derivatization reagent based on stable isotope labeling, and the chiral derivatization reagent can realize the separation and quantitative detection of more than 20 pairs of D / L-amino acids, and also has high sensitivity, accuracy, precision and stability, overcoming the technical difficulty that the existing chiral amino acid detection technology can only be used for the separation and quantification of a small amount of chiral amino acids, and laying a foundation for its application in the field of bladder cancer diagnosis.

[0009] Preferably, the chiral derivatization reagent based on stable isotope labeling in the present invention is prepared by the following steps: the first step is to react L-phenylalanine, paraformaldehyde or d 2 - Paraformaldehyde, 2,2,2-trifluoroethanol and sodium borohydride were stirred under reflux for a certain period of time and recrystallized from methanol-acetone to obtain a white powder d 0 -N,N-dimethylphenylalanine or d 4 -N,N-dimethylphenylalanine; In the second step, the product synthesized in the first step, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are dissolved in N,N-dimethylformamide, stirred at room temperature for reaction, purified by column chromatography after the stirring, concentrated, and dried to obtain a white powder. d 0 -N,N-dimethylphenylalanine succinimidyl ester or d 4 -N,N-Dimethylphenylalanine succinimidyl ester.

[0010] The beneficial effect is that the preparation method of the present invention is simple to operate and is conducive to the batch synthesis of the target product d0 / d4-N,N-dimethylphenylalanine succinimide ester.

[0011] The present invention also provides a chiral amino acid detection kit for use in diagnosing recurrent bladder cancer. The amino acid standard substances include D-Val, D-Leu / D-Ile, L-Val, L-Pro, L-Ile, L-Asn, D-Thr, D-Asp%, L-Leu and D-Glu standard substances. The D-Val, D-Leu / D-Ile, L-Val, L-Pro, L-Ile, L-Asn, D-Thr, D-Asp, L-Leu and D-Glu in the kit can be used as markers for primary bladder cancer. d 0 / d 4-N,N-dimethylphenylalanine succinimide ester is used as a derivatization reagent to derivatize urine samples and determine the amino acids and their contents in urine samples. According to experiments, the kit of the present invention shows high specificity, sensitivity and accuracy for primary bladder cancer, and its detection cost is low, which is conducive to clinical promotion and application.

[0012] The present invention also provides an application of a chiral amino acid detection kit in diagnosing recurrent bladder cancer. The amino acid standards in the chiral amino acid detection kit include standards of L-His, D-Gln, L-Abu, L-Gln, L-Asn, L-Val, D-Trp, D-Abu, D-Tyr and D-Asn. In actual detection, a urine sample is used as the detection object, L-His, D-Gln, L-Abu, L-Gln, L-Asn, L-Val, D-Trp, D-Abu, D-Tyr and D-Asn are used as markers, and d 0 / d 4 -N,N-dimethylphenylalanine succinimide ester is used as a derivatization reagent to derivatize urine samples and determine the amino acids and their contents in the urine samples, and the recurrence of bladder cancer in patients is quickly judged based on the markers. The kit of the present invention shows high specificity, sensitivity and accuracy for recurrent bladder cancer, has low detection cost, and has important clinical promotion value. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 In Example 1 d 0 -N,N-dimethylphenylalanine hydrogen nuclear magnetic resonance spectrum.

[0014] Figure 2 In Example 1 d 0 -N,N-dimethylphenylalanine carbon nuclear magnetic resonance spectrum.

[0015] Figure 3 In Example 1 d 0 High-resolution mass spectrum of -N,N-dimethylphenylalanine.

[0016] Figure 4 In Example 1 d 0 -H NMR spectrum of N,N-dimethylphenylalanine succinimidyl ester.

[0017] Figure 5 In Example 1 d 0 -NMR carbon spectrum of N,N-dimethylphenylalanine succinimidyl ester.

[0018] Figure 6 In Example 2 d 4 -N,N-dimethylphenylalanine hydrogen nuclear magnetic resonance spectrum.

[0019] Figure 7 In Example 2 d 4 -N,N-dimethylphenylalanine carbon nuclear magnetic resonance spectrum.

[0020] Figure 8 In Example 2 d 4 High-resolution mass spectrum of -N,N-dimethylphenylalanine.

[0021] Fig. 9 This is a diagram showing the separation of chiral amino acids and glycine using the detection method constructed in Example 3.

[0022] Fig.10 This is the ROC curve of D-Val, D-Leu / D-Ile, L-Val, L-Pro, L-Ile, L-Asn, D-Thr, D-Asp, L-Leu, and D-Glu as diagnostic markers for bladder cancer in Example 5.

[0023] Fig.11 This is the ROC curve of L-His, D-Gln, L-Abu, L-Gln, L-Asn, L-Val, D-Trp, D-Abu, D-Tyr, and D-Asn as bladder cancer recurrence monitoring markers in Example 6. DETAILED DESCRIPTION

[0024] The embodiments of the present invention are described in detail below in conjunction with the accompanying drawings. It should be noted that the chemical reagents used in the present invention are existing commercially available reagents, and the present invention uses HPLC-MS / MS to detect amino acid derivatives, wherein the ultra-high performance liquid chromatography uses the LC-30AD (Japan, Shimadzu Corporation) system, and the chromatographic column uses the Acquity UPLC BEH C18 (1.7 μm particle size, 1502.1 mm); the mass spectrometer uses a 6500 Q-TRAP mass spectrometer equipped with an ion-driven turbine ESI source (USA, ABSCIEX).

[0025] The amino acids in the embodiments of the present invention include alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), methionine (Met), proline (Pro), tryptophan (Trp), serine (Ser), tyrosine (Tyr), phenylalanine (Phe), asparagine (Asn), glutamine (Gln), threonine (Thr), aspartic acid (Asp), glutamic acid (Glu), lysine (Lys), arginine (Arg), histidine (His), homoserine (Homoser), ornithine (Orn), citrulline (Cit), cis-4-hydroxy-proline (cis-4-OH-Pro), trans-4-hydroxy-proline (trans-4-OH-Pro), kynurenine (Kynu), 2-aminobutyric acid (Abu), and glycine (Gly).

[0026] Example 1 The present invention d 0 Synthesis of N,N-dimethylphenylalanine succinimidyl ester The present invention d 0 -N,N-dimethylphenylalanine succinimide ester is synthesized by a two-step method, specifically including: first step, d 0 - Synthesis of N,N-dimethylphenylalanine Weigh 3.3038 g L -phenylalanine, 4.0805g paraformaldehyde were added to a flask, and then 100 mL TFE was added; then 3.0264 g NaBH4 was added, and the reaction was stirred under reflux conditions; after the reaction was completed, it was recrystallized with methanol-acetone and dried to obtain a white powder d 0 -N,N-dimethylphenylalanine, d 0 The hydrogen spectrum, carbon spectrum and mass spectrum of -N,N-dimethylphenylalanine are shown in Figure 1 , Figure 2 and Figure 3 , the corresponding data are as follows: 1 H NMR (400 MHz, D2O) δ: 7.34-7.22 (m, 5H), 3.75 (dd, J1 = 9.1 Hz, J2= 5.8 Hz, 1H), 3.26 (dd, J1 = 13.7 Hz, J2 = 5.8 Hz, 1H), 3.03 (dd, J1 = 13.7Hz, J2 = 9.2Hz, 1H), 2.85 (s, 6H); 13C NMR (101 MHz, D2O) δ: 172.2, 135.2,129.2, 128.9, 127.4, 72.1, 41.6, 34.0; ESI-MS: [M+H] + , m / z194.1178; After identification, in this embodiment d 0 -N,N-dimethylphenylalanine has the following structural formula: ; Step 2: d 0 Synthesis of N,N-dimethylphenylalanine succinimidyl ester 101.3 mg d 0 -N,N-dimethylphenylalanine, 74.2 mg N-hydroxysuccinimide and 113.3 mg 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride were dissolved in 4 mL N,N-dimethylformamide (DMF) and stirred at room temperature for 36 h. After the reaction was clear, it was purified by column chromatography, then concentrated by rotary evaporation, and dried in vacuo to obtain a white powder. d 0 -N,N-dimethylphenylalanine succinimide ester; wherein, d 0 The hydrogen and carbon spectra of -N,N-dimethylphenylalanine succinimide ester are shown in Figure 4-Figure 5 , the corresponding data are as follows: 1 H NMR (400 MHz, CD2Cl2) δ: 7.24-7.13 (m, 5H), 3.71 (t, J = 7.3Hz,1H), 3.08-2.91 (m, 2H), 2.71 (s, 4H), 2.36 (s, 6H). 13 C NMR (101 MHz, CD2Cl2)δ: 169.1, 166.2, 137.4, 129.2, 128.4, 126.7, 66.9, 40.9, 35.7, 25.7; After identification, in this embodiment d 0 -N,N-dimethylphenylalanine succinimide ester has the structural formula: .

[0027] Example 2 The present invention d 4 Synthesis of N,N-dimethylphenylalanine succinimidyl ester first step, d 4 -Synthesis of N,N-dimethylphenylalanine The difference between the first step in this embodiment and that in embodiment 1 is that: d 2 -paraformaldehyde is substituted for the paraformaldehyde in Example 1 to synthesize d 4 - N,N -dimethylphenylalanine, its hydrogen spectrum, carbon spectrum and mass spectrum are shown in Figure 6 , Figure 7 and Figure 8 , the corresponding data are as follows: 1 H NMR (400 MHz, D2O) δ: 7.35-7.24 (m, 5H), 3.75 (dd, J1 = 9.0 Hz, J2= 5.9 Hz, 1H), 3.24 (dd, J1 = 13.8 Hz, J2 = 5.8 Hz, 1H), 3.03 (dd, J1 = 13.7,J2 = 9.1Hz, 1H), 2.81 (s, 2H); 13 C NMR (101 MHz, D2O) δ: 172.2, 135.3, 129.2,128.9, 127.4, 72.0, 41.1, 33.7; ESI-MS: [M+H] + , m / z198.1429; After identification, in this embodiment d 4 -N,N-dimethylphenylalanine has the following structural formula: ; Step 2: d 4 Synthesis of N,N-dimethylphenylalanine succinimidyl ester The difference between the second step in this embodiment and that in embodiment 1 is that: d 4 -N,N-dimethylphenylalanine replaces the d 0 -N,N-dimethylphenylalanine, synthesized d 4 -N,N-dimethylphenylalanine succinimide ester, its structural formula is as follows: .

[0028] Example 3 Chiral Amino Acid Kit of the Present Invention The chiral amino acid kit of this embodiment includes d 0 -N,N-dimethylphenylalanine succinimide ester, d 4 -N,N-dimethylphenylalanine succinimide ester and amino acid standard solution, the amino acid standard solution includes D / L-Ala, D / L-Val, Leu, D / L-Ile, D / L-Met, D / L-Pro, D / L-Trp, D / L-Ser, D / L-Tyr, D / L-Phe, D / L-Asn, D / L-Gln, D / L-Thr, D / L-Asp, D / L-Glu, D / L-Lys, D / L-Arg, D / L-His, D / L-Homoser, D / L-Orn, D / L-Cit, cis-4-OH-Pro, trans-4-OH-Pro, D / L-Kynu, D / L-Abu and Gly. The detection method of the chiral amino acid kit includes the following contents: 1. The present invention is based on the synthesis of Example 1-2 d 0 / d 4 -N,N-dimethylphenylalanine succinimide ester, a detection method for chiral amino acids is constructed. The present invention takes the separation and detection of known D / L amino acids as an example to explain the detection method in detail, specifically including the following contents: Prepared with acetonitrile / water (v:v = 5:1) d 0 - N,N-dimethylphenylalanine succinimidyl ester solution and d 4 - N,N-dimethylphenylalanine succinimide ester solution, the concentration was 10000 nmol / mL; 2.5 μL of 40mM D / L amino acid (or glycine) was added to the above reagents respectively, and the derivatization reaction was carried out at room temperature for 10 min. After the reaction, the sample was concentrated with a concentrator and then re-dissolved with 500 μL of water to obtain d 0 -N,N-dimethylphenylalanine succinimidyl ester - amino acids and d 4 -N,N-dimethylphenylalanine succinimidyl ester-amino acid (as internal standard) two derivatized amino acids, the two derivatized amino acids are mixed in a certain ratio; The mixed derivatized samples were analyzed by HPLC-MS / MS analysis. The liquid chromatography conditions were as follows: mobile phase A was 0.1% formic acid in water; mobile phase B was 0.1% formic acid in acetonitrile; the elution gradient of the mobile phase was: 1% B at 0 min, 1% B at 1 min, 12% B at 10 min, 30% B at 20 min, and 90% B at 23 min; the mass spectrometry conditions were as follows: ion source temperature was 550 °C; ion spray voltage was 5500 V; Gas 1, Gas 2 and Curtain gas were 55, 55 and 25 psi, respectively; multiple reaction monitoring (MRM) positive ion mode was used; The results of the separation spectrum of D / L-amino acids and the spectrum of glycine are shown in Fig. 9 .Depend on Fig. 9 It can be seen that the detection method constructed by the present invention can realize the separation of 20 pairs of chiral amino acids and can also realize the detection of glycine.

[0029] 2. When used for actual samples, taking urine samples as an example, the urine samples are first centrifuged to remove the precipitate, then filtered through a micro-membrane, and then added to the urine samples. d 0 -N,N-dimethylphenylalanine succinimidyl ester was derivatized and then a known concentration of d 4 -N,N-dimethylphenylalanine succinimide ester-amino acid standard solution, and then use HPLC-MS / MS to detect the mixed solution, so as to realize the detection and analysis of amino acids in urine samples.

[0030] III. Evaluation of the Kit of the Present Invention 1. Standard curve, detection limit and detection limit The present invention d 4 -N,N-dimethylphenylalanine succinimidyl ester-derivatized amino acids were used as internal standards, and the standard curve was drawn using the internal standard method, which specifically included the following contents: 400 pmol / mL d 4 -N,N-dimethylphenylalanine succinimide ester-amino acid derivative standard solution was used as internal standard and diluted stepwise with water d 0 -N,N-dimethylphenylalanine succinimide ester-amino acid derivative standard solution, the concentration of which is 0.4, 1, 4, 10, 40, 100, 400, 1000, 4000, 10000, 20000 pmol / mL; d 0 -N,N-dimethylphenylalanine succinimidyl ester-amino acid derivative standard solution and d 4-N,N-dimethylphenylalanine succinimide ester-amino acid derivative standard solutions were mixed in proportions so that the concentration ratio of the two amino acid derivatives was 0.001:1, 0.0025:1, 0.01:1, 0.04:1, 0.1:1, 0.25:1, 1:1, 2.5:1, 10:1, 20:1, and 50:1; Each of the mixed solutions was subjected to HPLC-MS / MS detection according to the detection conditions of this embodiment, and then d 0 -N,N-dimethylphenylalanine succinimidyl ester - amino acids and d 4 The concentration ratio of -N,N-dimethylphenylalanine succinimide ester-amino acid was used as the horizontal axis, and the area ratio of the two amino acid derivatives was used as the vertical axis to draw a standard curve, and the LOD and LOQ of each amino acid were analyzed. The results are shown in Table 1.

[0031] Table 1 Standard curves, LOD and LOQ of amino acids As can be seen from the table above, the above amino acids have a good linear relationship in the range of 0.2 to 20000 pmol / ml, and the correlation coefficient R 2 All of them are above 0.996, indicating that the detection method of the present invention is reliable; in addition, the LOD of the above amino acids is 0.12-11.5385 fmol, and the LOQ is 0.40-38.4615 fmol, further indicating that the detection method of the present invention has high sensitivity, accuracy and precision.

[0032] 2. Accuracy The amino acid standard solutions of three different concentrations, low, medium and high, were tested according to the detection method in Example 3, and the accuracy of each amino acid was calculated, as shown in Table 2.

[0033] Table 2 Accuracy of amino acids As can be seen from the above table, the accuracy of the above three different concentrations of amino acids is between 85% and 115%, indicating that the detection method of the present invention has high accuracy.

[0034] 3. Precision The present invention investigates the intra-day precision and inter-day precision of the detection method for each amino acid. The intra-day precision is to perform HPLC-MS / MS analysis on low, medium and high amino acid derivatized standard solutions three times on the same day, and the inter-day precision is to perform HPLC-MS / MS analysis on three amino acid derivatized standard solutions of different concentrations (low, medium and high) for three consecutive days. As shown in Table 3, the RSD values ​​of the intra-day precision and inter-day precision of each amino acid are both lower than 10%, indicating that the present invention has high precision.

[0035] Table 3 Intra-day precision and inter-day precision of the present invention 4. Stability A set of low, medium and high concentration amino acid standard solutions were stored at 4°C for two days, and another set of amino acid standard solutions were stored at -20°C for 5 days, and then the two sets of amino acids were tested and analyzed according to the detection method of this embodiment. The coefficient of variation CV values ​​of the amino acids were all lower than 8% (see Table 4), indicating that the present invention has good stability.

[0036] Table 4 Stability of the present invention In summary, the present invention uses d 0 / d 4 -N,N-dimethylphenylalanine succinimidyl ester was used as a derivatization reagent and the internal standard method was used for the quantitative analysis of amino acids, which not only showed high sensitivity and accuracy, but also had good precision and stability.

[0037] Example 5 This embodiment provides a chiral amino acid detection kit for diagnosing primary bladder cancer, comprising d 0 -N,N-dimethylphenylalanine succinimide ester, d 4 -N,N-dimethylphenylalanine succinimide ester and ten amino acid standards including D-Val, D-Leu / D-Ile, L-Val, L-Pro, L-Ile, L-Asn, D-Thr, D-Asp, L-Leu and D-Glu. The kit uses urine samples as the test object. d 0 -N,N-dimethylphenylalanine succinimide ester, d 4Derivatize urine samples with -N,N-dimethylphenylalanine succinimide ester respectively, adopt the detection method in Example 3, and determine the types and contents of amino acids in the urine samples according to the standard curve.

[0038] Analyze the urine samples of 110 newly diagnosed bladder cancer patients and 103 non-tumor controls using the kit of the present invention, draw the receiver operating characteristic (ROC) curve and calculate the area under the curve (AUC) to evaluate the sensitivity and specificity of D-Val, D-Leu / D-Ile, L-Val, L-Pro, L-Ile, L-Asn, D-Thr, D-Asp, L-Leu and D-Glu for the initial diagnosis of bladder cancer; among them, when AUC < 0.5, it indicates that the diagnosis is meaningless, when 0.5 < AUC < 0.7, it indicates that the diagnostic accuracy is relatively low, when 0.7 < AUC < 0.9, it indicates that the diagnostic accuracy is average, and when 0.9 < AUC < 1, it indicates that the diagnostic accuracy is relatively high.

[0039] The results show that the AUC values of D-Val, D-Leu / D-Ile, L-Val, L-Pro, L-Ile, L-Asn, D-Thr, D-Asp%, L-Leu and D-Glu are 0.972, and the sensitivity and specificity are 91.8% and 95.1% respectively, indicating that the present invention has high sensitivity and specificity for newly diagnosed bladder cancer, low detection cost, and has the prospect of clinical promotion.

[0040] Example 6 This example presents a kit for diagnosing recurrent bladder cancer, including d 0 -N,N-dimethylphenylalanine succinimide ester, d 4 -N,N-dimethylphenylalanine succinimide ester and standards of ten amino acids, namely L-His, D-Gln, L-Abu, L-Gln, L-Asn, L-Val, D-Trp, D-Abu, D-Tyr and D-Asn. This kit takes urine samples as the detection object and uses d 0 -N,N-dimethylphenylalanine succinimide ester, d 4 -N,N-dimethylphenylalanine succinimide ester to derivatize urine samples respectively, adopt the detection method in Example 3, and determine the types and contents of amino acids in the urine samples according to the standard curve.

[0041] The urine samples of 94 patients with recurrent bladder cancer and 108 patients without recurrence were analyzed using the kit of the present invention, and the receiver operating characteristic (ROC) curve was plotted and the area under the curve (AUC) was calculated to evaluate the sensitivity and specificity of L-His, D-Gln, L-Abu, L-Gln, L-Asn, L-Val, D-Trp, D-Abu, D-Tyr, and D-Asn for the diagnosis of recurrent bladder cancer; among them, when AUC < 0.5, it indicates that the diagnosis is meaningless, when 0.5 < AUC < 0.7, it indicates low diagnostic accuracy, when 0.7 < AUC < 0.9, it indicates general diagnostic accuracy, and when 0.9 < AUC < 1, it indicates high diagnostic accuracy.

[0042] The results showed that the AUC values of L-His, D-Gln, L-Abu, L-Gln, L-Asn, L-Val, D-Trp, D-Abu, D-Tyr, and D-Asn were 0.965, and the sensitivity and specificity were 91.5% and 89.8% respectively, indicating that the kit of the present invention can be used for the recurrence monitoring of bladder cancer.

Claims

1. A chiral amino acid detection kit, Features: It includes amino acid standards and derivatization reagents for derivatizing amino acid standards and samples containing amino acids; wherein, The amino acid standard comprises any one or a combination of two or more of D / L-Ala, D / L-Val, Leu, D / L-Ile, D / L-Met, D / L-Pro, D / L-Trp, D / L-Ser, D / L-Tyr, D / L-Phe, D / L-Asn, D / L-Gln, D / L-Thr, D / L-Asp, D / L-Glu, D / L-Lys, D / L-Arg, D / L-His, D / L-Homoser, D / L-Orn, D / L-Cit, D / L-Kynu, D / L-Abu and Gly; The derivatization reagent is a chiral derivatization reagent based on stable isotope labeling, including d 0 -N,N-dimethylphenylalanine succinimidyl ester and d 4 -N,N-dimethylphenylalanine succinimide ester, the general structural formula is: ; Among them, when R 1 CH 3 And R 2 CH 3 Time d 0 -N,N-dimethylphenylalanine succinimide ester, when R 1 For CHD 2 And R 2 For CHD 2 Time d 4 -N,N-Dimethylphenylalanine succinimidyl ester.

2. The chiral amino acid detection kit according to claim 1, Features: The chiral derivatization reagent based on stable isotope labeling is prepared by the following steps: In the first step, L-phenylalanine, paraformaldehyde or d 2 - Paraformaldehyde, 2,2,2-trifluoroethanol and sodium borohydride were stirred under reflux for a certain period of time and recrystallized from methanol-acetone to obtain a white powder d 0 -N,N-dimethylphenylalanine or d 4 -N,N-dimethylphenylalanine; In the second step, the product synthesized in the first step, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are dissolved in N,N-dimethylformamide, stirred at room temperature for reaction, purified by column chromatography after the stirring, concentrated, and dried to obtain a white powder. d 0 -N,N-dimethylphenylalanine succinimidyl ester or d 4 -N,N-Dimethylphenylalanine succinimidyl ester.

3. Use of the chiral amino acid detection kit according to claim 1 or 2 in diagnosing primary bladder cancer, Features: The amino acid standards include D-Val, D-Leu / D-Ile, L-Val, L-Pro, L-Ile, L-Asn, D-Thr, D-Asp%, L-Leu and D-Glu standards.

4. Use of the chiral amino acid detection kit according to claim 1 or 2 in diagnosing recurrent bladder cancer, Features: The amino acid standards include standards of L-His, D-Gln, L-Abu, L-Gln, L-Asn, L-Val, D-Trp, D-Abu, D-Tyr and D-Asn.